In this episode, Indrė Dryžienė, Head of Clinical Operations Project Management at Biomapas, is joined by Samson Fung, Managing Director of Fung Consulting Healthcare & Life Sciences, and Artūras Pažera, Senior Clinical Project Manager at Biomapas, to discuss key questions on how CRO selection shapes early-phase biotech success.
Choosing a CRO directly influences speed, feasibility, regulatory clarity, and study quality. Hence, for emerging biotechs planning early-phase and first-in-human studies, the right timing and partnership can prevent delays, strengthen operational efficiency, and improve decision-making from the very start.
During the discussion, we explore:
- The most common mistakes biotechs make when planning their first trial
- When sponsors should start thinking about their CRO partner
- What matters most when evaluating a CRO for early-phase studies
- How do smaller CROs compare to global providers in early oncology development
- How early regulatory or scientific advice can change the trajectory of a study
Whether you are preparing for your first-in-human study or scaling early-phase oncology programs, this conversation offers grounded, experience-driven guidance.
